{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.3","upperLimit":"9.4","value":"8.0"},{"groupId":"OG001","lowerLimit":"6.2","upperLimit":"10.3","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"103"}],"units":"Participants"}],"description":"Duration of response until disease progression, death, or date last seen among patients who responded.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 175 mg/m2 paclitaxel IV over 3 hours on day 1, carboplatin AUC 5 IV over 30 minutes on day 1, and 850 mg metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Paclitaxel, Carboplatin, Metformin Hydrochloride)"},{"description":"Patients receive 175 mg/m2 paclitaxel IV and carboplatin AUC 5 IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Paclitaxel, Carboplatin, Placebo)"}],"paramType":"MEDIAN","populationDescription":"Patients who responded","reportingStatus":"POSTED","timeFrame":"From the date of response to disease progression, death, or date last seen assessed up to 5 years","title":"Duration of Response by Treatment","type":"SECONDARY","unitOfMeasure":"Months"}